Keywords: lilly/daiichi, sankyo, prasugrel, cuts, cv, aes, vs

Lilly/Daiichi Sankyo's prasugrel cuts CV AEs 19% vs Plavix, but side effects raise doubts

Article | 21 November 2007

Print This

US drug major Eli Lilly reported positive findings from a late-stage trial of its antiplatelet drug prasugrel, showing that it ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in